Monte Rosa Therapeutics Ends Current ATM Equity Program

An update from Monte Rosa Therapeutics ( (GLUE) ) is now available.

Effective January 7, 2026, Monte Rosa Therapeutics, Inc. terminated the sales agreement prospectus tied to its at-the-market equity offering program under its existing registration statement, meaning it will no longer sell common stock under that prospectus unless and until it files new offering documents, while the underlying Sales Agreement with Jefferies LLC remains in force. By the time of the termination, the company had issued and sold 2,955,082 shares of common stock through the program, raising aggregate net proceeds of $24.2 million, signaling a pause in at-the-market equity issuance that could affect its near-term financing flexibility and capital-raising strategy.

The most recent analyst rating on (GLUE) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Monte Rosa Therapeutics stock, see the GLUE Stock Forecast page.

Spark’s Take on GLUE Stock

According to Spark, TipRanks’ AI Analyst, GLUE is a Outperform.

The score is driven primarily by the sharp TTM financial inflection (profitability and very strong free cash flow) and reinforced by positive clinical and partnership news flow. Offsetting factors include a high P/E valuation and only mixed near-term technical momentum despite a strong longer-term uptrend.

To see Spark’s full report on GLUE stock, click here.

More about Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc. is a biotechnology company focused on developing therapeutic products, with its capital structure funded in part through issuances of common stock to support its operations and growth in the life sciences sector.

Average Trading Volume: 1,137,585

Technical Sentiment Signal: Buy

Current Market Cap: $937.7M

For a thorough assessment of GLUE stock, go to TipRanks’ Stock Analysis page.